Zevra Therapeutics (ZVRA) Competitors $12.53 +0.51 (+4.24%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$12.46 -0.07 (-0.60%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMYShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Vericel Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Zevra Therapeutics (NASDAQ:ZVRA) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Does the media prefer ZVRA or VCEL? In the previous week, Zevra Therapeutics had 10 more articles in the media than Vericel. MarketBeat recorded 11 mentions for Zevra Therapeutics and 1 mentions for Vericel. Vericel's average media sentiment score of 0.93 beat Zevra Therapeutics' score of 0.92 indicating that Vericel is being referred to more favorably in the news media. Company Overall Sentiment Zevra Therapeutics Positive Vericel Positive Do analysts prefer ZVRA or VCEL? Zevra Therapeutics presently has a consensus target price of $23.71, indicating a potential upside of 89.26%. Vericel has a consensus target price of $61.14, indicating a potential upside of 53.13%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ZVRA or VCEL more profitable? Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-226.78% -201.05% -53.55% Vericel 1.25%1.09%0.73% Which has preferable valuation and earnings, ZVRA or VCEL? Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M29.02-$105.51M-$1.90-6.59Vericel$237.22M8.47$10.36M$0.031,331.00 Do institutionals & insiders have more ownership in ZVRA or VCEL? 35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, ZVRA or VCEL? Zevra Therapeutics has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. SummaryVericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$657.25M$2.74B$5.61B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-6.599.4228.1820.27Price / Sales29.02714.14428.6998.03Price / CashN/A165.3637.4658.16Price / Book16.934.608.045.49Net Income-$105.51M$31.26M$3.19B$250.45M7 Day Performance28.05%4.80%3.62%4.79%1 Month Performance33.72%5.42%4.06%7.68%1 Year Performance114.19%-4.36%30.00%16.43% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.1298 of 5 stars$12.53+4.2%$23.71+89.3%+105.1%$657.25M$23.61M-6.5920News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeVCELVericel3.5594 of 5 stars$41.79+0.8%$61.14+46.3%-19.2%$2.10B$237.22M1,393.30300AGIOAgios Pharmaceuticals4.3878 of 5 stars$36.06+2.0%$58.60+62.5%-12.0%$2.09B$36.50M3.21390Insider TradeAnalyst RevisionCGONCG Oncology2.4271 of 5 stars$26.90+0.8%$58.67+118.1%-22.5%$2.05B$1.14M-17.8161Analyst UpgradeGap DownKNSAKiniksa Pharmaceuticals International3.5467 of 5 stars$27.86+1.5%$38.80+39.3%+30.0%$2.03B$423.24M-111.42220Positive NewsAnalyst ForecastBEAMBeam Therapeutics2.3037 of 5 stars$20.02+0.7%$48.75+143.5%-18.2%$2.01B$63.52M0.00510News CoverageIDYAIDEAYA Biosciences3.6232 of 5 stars$22.09+0.8%$53.42+141.8%-43.3%$1.94B$7M-6.1580News CoverageAnalyst UpgradeIRONDisc Medicine3.2354 of 5 stars$54.75+3.0%$96.70+76.6%+21.3%$1.90BN/A0.0030Insider TradeBLTEBelite Bio2.3707 of 5 stars$59.74+5.2%$96.67+61.8%+29.2%$1.89BN/A0.0010News CoverageAnalyst RevisionGap UpCNTACentessa Pharmaceuticals3.2651 of 5 stars$14.34+4.3%$27.89+94.6%+50.8%$1.88B$6.85M0.00200HRMYHarmony Biosciences4.8647 of 5 stars$32.09-0.1%$53.63+67.1%+2.0%$1.85B$714.73M12.27200News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Vericel Alternatives Agios Pharmaceuticals Alternatives CG Oncology Alternatives Kiniksa Pharmaceuticals International Alternatives Beam Therapeutics Alternatives IDEAYA Biosciences Alternatives Disc Medicine Alternatives Belite Bio Alternatives Centessa Pharmaceuticals Alternatives Harmony Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
